Hande Z. Turna - Publications

Comparative Prognostic Value of Systemic Inflammation-Based Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with First-Line Immunotherapy.

Journal: Biomedicines

Published: June 12, 2026

Effect of body mass index on immune checkpoint inhibitor efficacy in patients with advanced cancer.

Journal: Tumori

Published: November 07, 2024

Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: August 01, 2024

Effects of immune related adverse events and corticosteroids on the outcome of patients treated with immune checkpoint inhibitors.

Journal: Scientific reports

Published: July 17, 2024

Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study.

Journal: Current medical research and opinion

Published: May 29, 2024

The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study.

Journal: Breast cancer research and treatment

Published: December 14, 2023

3-4 Cycles versus 6 Cycles Neoadjuvant Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: Survival Is Not Determined by the Number of Neoadjuvant Chemotherapy Cycles.

Journal: Chemotherapy

Published: September 08, 2023

Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 16, 2023

Radiation recall myositis with pazopanib in a patient with soft tissue sarcoma.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: June 15, 2023

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 28, 2022

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 30, 2022

The Predictive Importance of Body Mass Index on Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer.

Journal: Breast care (Basel, Switzerland)

Published: May 15, 2022